IP Library Granted Patent US 11,439,659
Granted Patent B2
US 11,439,659 · App. 16/702,525 · Granted Sep 13, 2022

Methods and compositions to prevent and treat inflammation and allergic reactions

Inventors: Richard L. Gallo (San Diego, CA); Tatsuya Dokoshi (La Jolla, CA)
Assignee: The Regents of the University of California
A61K31/713A61K31/702A61K31/728A61K38/47A61P31/04C12N9/16C12N9/2474
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,439,659
App. No.
16/702,525
Granted
Sep 13, 2022
Kind
B2
Abstract

The disclosure relates to compositions and methods for treating infection, allergic reactions, colitis, IBD, contact dermatitis, psoriasis, atopic dermatitis, graft vs. host disease and disorders and other disease and disorders comprising dendritic cell activation as well as compositions and method to improve allergen sensitization.

Claims (20)

1. A composition comprising therapeutically effective amounts of substantially purified oligosaccharide fragments of hyaluronan (OligoHA) and/or therapeutically effective amounts of a substantially purified enzyme that degrades hyaluronan into oligosaccharide fragments, wherein the composition comprises 60% or more by weight of a combination of tri-, tetra- and hexa-saccharide fragments of hyaluronan.

2. The composition of claim 1 , wherein the composition comprises 80% or more by weight or by composition of a combination of tri-, tetra-, and hexa-saccharide fragments of hyaluronan.

3. The composition of claim 1 , wherein the composition is formulated for topical or oral administration to a subject in need thereof.

4. The composition of claim 1 , wherein the composition comprises OligoHA and an enzyme that degrades hyaluronan into oligosaccharide fragments, wherein the enzyme is selected from the group consisting of: a hyaluronidase derived from humans, a hyaluronidase derived from Streptomyces, a hyaluronidase SD, a chondroitinase ACI, a chondroitinase ACIII, a chondroitinase ABC and an endoglucuronidase derived from leeches.

5. A method to reduce or inhibit inflammation in a subject in need of treatment thereof, comprising:

administering a therapeutically effective amount of the composition of claim 1 to the subject.

6. The method of claim 5 , wherein the inflammation is associated with an inflammatory disease or disorder, or associated with a bacterial infection.

7. The method of claim 6 , wherein the inflammatory disease or disorder is selected from the group consisting of ulcerative colitis, inflammatory bowel disease, Crohn's disease, dermatitis, psoriasis, sinusitis, active hepatitis, asthma, rheumatoid arthritis, osteoarthritis, vasculitis, lupus, and fibromyalgia.

8. A method to reduce or inhibit adipogenesis and/or adipocyte differentiation in a subject in need of treatment thereof, comprising:

administering a therapeutically effective amount of the composition of claim 1 to the subject.

9. The method of claim 8 , wherein the composition is topically administered to reduce or inhibit adipogenesis and/or adipocyte differentiation in dermal and/or hypodermal tissue.

10. The method of claim 8 , wherein the composition is orally administered to reduce or inhibit adipogenesis and/or adipocyte differentiation in the gastrointestinal track.

11. The method of claim 10 , wherein the adipogenesis and/or adipocyte differentiation in the gastrointestinal track is associated with an inflammatory gastrointestinal disorder or disease.

12. A method to promote sensitization to an antigen/allergen in a subject, comprising:

administering a therapeutically effective amount of the composition of claim 1 to the subject; and

delivering an antigen/allergen to the subject.

13. The method of claim 12 , wherein the composition is administered prior to, simultaneously with, or immediately after delivering the antigen/allergen to the subject.

14. The method of claim 12 , wherein administration of the composition prior to the delivering the antigen/allergen induces anergy in the subject.

15. The method of claim 13 , wherein the composition is administered within 1 minute to 30 minutes of the delivery of the antigen/allergen to the subject.

16. The method of claim 12 , wherein administration of the composition induces dendritic cell maturation and/or migration.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 2, 2022
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061053/0294 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2020
From: GALLO, RICHARD L.; DOKOSHI, TATSUYA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 051417/0390 →
Continuity (2)
Provisional Application 62774426 · Dec 3, 2018
Related Publication 20200188420A1 · Jun 18, 2020